Inventor Of R-salbutamol Dr Gunnar Aberg Joins Board of Perth-based Biotechnology Firm Stirling Products Limited

The Inventor Of R-salbutamol Dr Gunnar Aberg Has Joined The Board of Perth-based Biotechnology Firm Stirling Products Limited

(PRWEB) March 18, 2005 -- Perth-based biotechnology company Stirling Products Limited (ASX: STI) has strengthened its Board of Directors with the appointment of the inventor of its major animal growth promoter.

New Non-Executive Director, Dr Gunnar Aberg is one of the original
developers and patent holders for R-salbutamol to which Stirling Products acquired global rights for use in growth promotion.

"This is an exciting development for the company and adds to our expertise as a leader in the application of new technology to animal health and nutrition," said Stirling Managing Director, Dr Calvin London.

Dr Aberg is CEO of the Florida-based Bridge Pharma Inc, a company
established to fulfil an increasing demand for developing therapeutic drugs that conform to high international standards.

Bridge Pharma is also the largest shareholder in Stirling Products with an 11 per cent share in the company.

"Dr Aberg will bring added depth to our Board because of his immense
experience in intellectual property development and commercialization, including an intimate knowledge of our lead product ST810," Dr London said.

ST810 fine-tunes the metabolism in animals to produce more lean muscle and less fat in a range of animal species.

About Stirling Products
Stirling Products is commercializing patented animal growth promoters that turn fat into protein and improve feed efficiencies in poultry, sheep, pigs, cattle and fish.

These products will play a major role in reducing the global use of
antibiotics and steroids for animal growth promotion.

About Dr Gunnar Aberg
Prior to founding Bridge Pharma, Dr. Aberg held senior research management positions in major European and US pharmaceutical companies. He has been involved in research and development that has successfully guided numerous pharmaceuticals onto the market including local anaesthetics, antiarrhythmics, antiasthmatics, antihypertensives, and antihistamines. Dr Aberg holds over 400 international and over 50 US patents.

For All Media Enquiries Contact: Managing Director, Dr Calvin London on:
T: (08) 9480 1480, M: 0400 204616 or
E: calvin.london@stirlingproducts.net
W: http://www.stirlingproducts.net

# # #